Yasutoshi Sakamoto
Overview
Explore the profile of Yasutoshi Sakamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bando H, Naito Y, Yamada T, Fujisawa T, Imai M, Sakamoto Y, et al.
Int J Clin Oncol
. 2024 Dec;
30(2):172-179.
PMID: 39714567
Background: The implementation of cancer precision medicine in Japan is deeply intertwined with insurance reimbursement policies and requires case-by-case reviews by Molecular Tumor Boards (MTBs), which impose considerable operational burdens...
2.
Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, et al.
Cancer Discov
. 2024 Jul;
14(11):2243-2261.
PMID: 39023403
The SCRUM-Japan MONSTAR-SCREEN consortium is a nationwide molecular profiling project employing artificial intelligence-driven multiomics analyses for patients with advanced malignancies, aiming to develop novel therapeutics and diagnostics and deliver effective...
3.
Fujii S, Katada C, Watanabe H, Shimoda T, Ochiai A, Yokoyama T, et al.
Cancer Sci
. 2024 Jul;
115(9):3169-3179.
PMID: 39009471
Narrow-band imaging combined with magnified endoscopy has enabled the detection of superficial squamous cell carcinoma of the head and neck (SSCCHN) that has been resected with minimally invasive treatment, preserving...
4.
Katada C, Yokoyama T, Watanabe A, Hara H, Yoshii T, Fujii H, et al.
Int J Radiat Oncol Biol Phys
. 2024 Jul;
120(5):1353-1362.
PMID: 38969179
Purpose: This study aimed to assess the viability of definitive chemoradiotherapy (dCRT) as an organ-preservation strategy for remarkable responders who were downstaged to stage IA after receiving induction chemotherapy for...
5.
Bando H, Misumi T, Sakamoto Y, Takeda Y, Nakamura Y, Mizuguchi K, et al.
Clin Colorectal Cancer
. 2024 Apr;
23(2):111-117.
PMID: 38679555
The extraction of data that contribute to regulatory approval from real-world data (RWD) is difficult because of the lack of a standardized data format and extraction methodology. Additionally, when real-world...
6.
Katada C, Yokoyama T, Hirasawa D, Iizuka T, Kikuchi D, Yano T, et al.
Am J Gastroenterol
. 2023 Jan;
118(7):1175-1183.
PMID: 36624037
Introduction: Curative management after endoscopic resection (ER) for esophageal squamous cell carcinoma (ESCC), which invades the muscularis mucosa (pMM-ESCC) or shallow submucosal layer (pSM1-ESCC), has been controversial. Methods: We identified...
7.
Sakamoto Y, Bando H, Nakamura Y, Hasegawa H, Kuwaki T, Okamoto W, et al.
Clin Colorectal Cancer
. 2022 Nov;
22(1):45-52.
PMID: 36376197
Utilizing real-world data (RWD) for effective clinical implementation is becoming more and more appealing as the cost of drug development rises, especially for patients with rare diseases and rare molecular...
8.
Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, et al.
Nat Med
. 2021 Nov;
27(11):1899-1903.
PMID: 34764486
The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment of patients with cancer in clinical trials has not been established. We conducted a phase 2 trial to evaluate...
9.
Katada C, Muto M, Fujii S, Yokoyama T, Yano T, Watanabe A, et al.
Cancer Med
. 2021 May;
10(12):3848-3861.
PMID: 33991076
Head and neck cancers, especially in hypopharynx and oropharynx, are often detected at advanced stage with poor prognosis. Narrow band imaging enables detection of superficial cancers and transoral surgery is...
10.
Katada C, Sugawara M, Hara H, Fujii H, Nakajima T, Ando T, et al.
Jpn J Clin Oncol
. 2020 Nov;
51(2):199-204.
PMID: 33147611
Background: An exploratory study was designed to evaluate the efficacy of granulocyte colony stimulating factor support for chemotherapy consisting of docetaxel, cisplatin and 5-fluorouracil chemotherapy in patients with oesophageal cancer....